Biohaven Ltd Share Price Today: Live Updates & Key Insights

Biohaven Ltd share price today is $9.11, up -0.33%. The stock opened at $8.9 against the previous close of $8.96, with an intraday high of $9.27 and low of $8.855.

Biohaven Ltd Share Price Chart

Biohaven Ltd

us-stock
To Invest in {{usstockname}}
us-stock

Biohaven Ltd Share Price Performance

$9.11 -0.0033(-0.33%) BHVN at 23 Mar 2026 12:12 PM Biotechnology
Lowest Today 8.855
Highest Today 9.27
Today’s Open 8.9
Prev. Close 8.96
52 Week High 31.18
52 Week Low 7.48
Day’s Range: Low 8.855 High 9.27
52-Week Range: Low 7.48 High 31.18
1 day return -
1 Week return -7.15
1 month return -22.77
3 month return -18.59
6 month return -39.81
1 year return -71.16
3 year return -30.78
5 year return -
10 year return -

Biohaven Ltd Institutional Holdings

Suvretta Capital Management, LLC 6.84

BlackRock Inc 5.24

HHG PLC 4.50

Stifel Financial Corp 4.40

Vanguard Group Inc 2.92

State Street Corp 2.83

State Street® SPDR® S&P® Biotech ETF 2.32

BB Biotech AG Ord 1.86

D. E. Shaw & Co LP 1.79

FMR Inc 1.78

JPMorgan Chase & Co 1.78

Geode Capital Management, LLC 1.59

iShares Russell 2000 ETF 1.52

BNP Paribas Arbitrage, SA 1.39

T. Rowe Price Associates, Inc. 1.34

Fidelity Select Biotechnology 1.31

Janus Henderson Glb Life Scn I2 USD 1.24

Citadel Advisors Llc 1.16

Schonfeld Strategic Advisors LLC 1.07

Balyasny Asset Management LLC 1.06

The Goldman Sachs Group Inc 1.05

Qube Research & Technologies 1.04

AQR Capital Management LLC 0.97

American Funds SMALLCAP World A 0.94

Capital Research Global Investors 0.89

HBM Healthcare Investments AG Ord 0.88

Millennium Management LLC 0.88

Vanguard Institutional Extnd Mkt Idx Tr 0.82

T. Rowe Price Health Sciences 0.81

Simplify Health Care ETF 0.69

Fidelity Small Cap Index 0.61

iShares Biotechnology ETF 0.55

iShares Russell 2000 Growth ETF 0.52

abrdn Life Sciences Investors 0.46

Vanguard Strategic Equity Inv 0.41

T. Rowe Price Integrated US SmCapGrEq 0.41

T. Rowe Price Integrated US Sm Gr Eq 0.41

Fidelity Extended Market Index 0.40

Schwab US Small-Cap ETF™ 0.37

State St Russell Sm/Mid Cp® Indx SL Cl I 0.36

Biohaven Ltd Market Status

Strong Buy: 11

Buy: 4

Hold: 1

Sell: 0

Strong Sell: 0

Biohaven Ltd Fundamentals

Market Cap 1343.26 M

PB Ratio 25.8828

PE Ratio 0.0

Enterprise Value 1313.21 M

Total Assets 451.45 M

Volume 6124425

Biohaven Ltd Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:462509000 462.5M, FY20:0 0.0M, FY19:null 0.0M

Annual Profit FY23:-3369000 -3.4M, FY22:null 0.0M, FY21:370845000 370.8M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-408168000 -408.2M, FY22:-570279000 -570.3M, FY21:-213796000 -213.8M, FY20:-118668000 -118.7M, FY19:-528805000 -528.8M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-1105000 -1.1M, Q2/2025:null 0.0M, Q1/2025:-1014999 -1.0M, Q3/2024:null 0.0M, Q2/2024:-977000 -1.0M

Quarterly Net worth Q3/2025:-173443000 -173.4M, Q2/2025:-198147000 -198.1M, Q1/2025:-221677000 -221.7M, Q3/2024:-160304000 -160.3M, Q2/2024:-319771000 -319.8M

About Biohaven Ltd & investment objective

Company Information Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Organisation Biotechnology

Employees 274

Industry Biotechnology

CEO Dr. Vladimir Coric M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Biohaven Ltd FAQs

What is the share price of Biohaven Ltd today?

The current share price of Biohaven Ltd is $9.11.

Can I buy Biohaven Ltd shares in India?

Yes, Indian investors can buy Biohaven Ltd shares by opening an international trading and demat account with Motilal Oswal.

How to buy Biohaven Ltd shares in India?

You can easily invest in Biohaven Ltd shares from India by:

Can I buy fractional shares of Biohaven Ltd?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Biohaven Ltd?

Biohaven Ltd has a market cap of $1343.26 M.

In which sector does Biohaven Ltd belong?

Biohaven Ltd operates in the Biotechnology sector.

What documents are required to invest in Biohaven Ltd stocks?

To invest, you typically need:

What is the PE and PB ratio of Biohaven Ltd?

The PE ratio of Biohaven Ltd is N/A and the PB ratio is 25.88.